The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
May 19th 2024
Atopic dermatitis (AD) in visible areas significantly impacts the romantic relationships, occupations, and sexual health of French female adult patients, according to a new study.
Childhood Maltreatment Associated With Atopic Disease
December 9th 2022Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis.
Read More
Dr Jason Ezra Hawkes on Advances in Clinical Research and Gaps in Knowledge for Atopic Dermatitis
November 24th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on how clinical studies in atopic dermatitis (AD) are increasingly investigating topics that remain unknown for disease management, including primary vs secondary failures and AD pathophysiology across different ethnic groups.
Watch
High Burden of AD, Bacterial Skin Infections Seen in Young Urban-Living Indigenous People
November 20th 2022Urban-living Indigenous children and young people in high-income countries reported a higher likelihood of current and severe symptoms of atopic dermatitis (AD) compared with a non-Indigenous population, as well as a higher incidence of bacterial skin infections.
Read More
Dr Jason Ezra Hawkes: Education on Chronic Nature, Subtypes of AD Key in Managing Diverse Patients
November 18th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed why it is important for dermatologists to educate patients on atopic dermatitis (AD) and keep an open mind on variations in disease presentation by skin color.
Watch
Topical Calcineurin Inhibitors for AD Not Associated With Cancer
November 14th 2022Pimecrolimus and tacrolimus, 2 topical calcineurin inhibitors for the treatment of atopic dermatitis (AD), were not shown to increase the risk of cancer based on moderate-certainty evidence from a systematic review and meta-analysis.
Read More
Investigating Real-World Effectiveness of Disease-Modifying Therapies in AD by Skin Type
November 10th 2022Real-world patients with atopic dermatitis with dark skin types showed greater mean reduction in disease severity between baseline and 6 months with dupilumab compared with those with light skin types, whereas no differences were observed regarding severity reduction for methotrexate and ciclosporin.
Read More
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed how prior authorizations and other insurance requirements are limiting treatment access in atopic dermatitis and how dermatologists can help ameliorate these approval issues.
Watch
Dupilumab Efficacy in AD Not Affected by Age of Disease Onset
October 25th 2022Dupilumab exhibited similarly significant and sustained improvements in atopic dermatitis (AD) signs, symptoms, and quality of life of adult patients with moderate to severe AD, regardless of age of disease onset, compared with placebo.
Read More
A digitally delivered targeted intervention of symptom and trigger education, treatment reminders, lifestyle coaching, and healthy lifestyle support demonstrated significant improvements in treatment adherence and related clinical outcomes among Icelandic patients with atopic dermatitis.
Read More
Dr Jason Ezra Hawkes Addresses Immunotherapy Innovation, Uptake Issues in Atopic Dermatitis
October 6th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed recent advancements in immunotherapy for atopic dermatitis and what unmet needs persist to address uptake issues and patient-specific care needs.
Watch
Skin Biomarkers Found to Predict Development of Pediatric Atopic Dermatitis
September 26th 2022Significant alterations were observed in lipid levels and other skin biomarkers for infants who developed atopic dermatitis (AD) vs controls, with phytosphingosine associated with the highest AD prediction accuracy.
Read More
Dr Jason Ezra Hawkes Discusses Clinical Considerations for Biologic Treatment in Atopic Dermatitis
September 24th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on the importance of shared decision-making in deciding which biologic would best alleviate disease burden in patients with moderate to severe atopic dermatitis.
Watch
Dr Jason Ezra Hawkes on Diagnostic Challenges, Strategies in Atopic Dermatitis
September 10th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on diagnostic challenges for atopic dermatitis and tips for clinicians in screening for the condition.
Watch
Dr Jason Ezra Hawkes Discusses How AD Immunology Informs Screening Practices
August 26th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, explained the utility of type 2 inflammation pathways and the microbiome in understanding the immune dysregulation associated with atopic dermatitis (AD).
Watch
Benefits of Dietary Elimination May Not Outweigh Risks in Atopic Dermatitis
August 23rd 2022Findings of a meta-analysis show that use of dietary elimination had a minimal effect on the severity of atopic dermatitis and may increase the risk of developing immunoglobulin E–mediated food allergy.
Read More
Drug Survival of Dupilumab Affected by Immunosuppressive Therapy, Older Age in AD
August 18th 2022Investigator Global Assessment score of very severe atopic dermatitis (AD) was associated with dupilumab discontinuation due to adverse effects, although generally adequate 1-, 2-, and 3-year drug survival rates were also observed.
Read More
Race, Insurance Type Among Predictors of Depressive Symptoms in Atopic Dermatitis
August 10th 2022Most patients with atopic dermatitis had flunctuating levels of depressive symptoms, with having public or no insurance, more severe itch, and skin pain cited as additional predictors of adverse mental health outcomes.
Read More
Overuse of Systemic Corticosteroids, Substantial Cost Burden for AD Seen in Germany
July 29th 2022Systemic corticosteroids were more commonly prescribed vs other systemic drug options in Germany for patients with atopic dermatitis (AD) despite their unfavorable risk-benefit profile, with a substantial economic burden cited among these populations.
Read More
Dr Elaine Siegfried Discusses Step Edits, Barriers to AD Treatment
July 23rd 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on step edits and other barriers limiting access to biologic, topical, and other medications for the treatment of atopic dermatitis (AD).
Watch